Puma Biotechnology stock jumped 9.7% to US$8.91 after earnings, a sharp move for a small oncology player that investors usually treat with caution. The immediate catalyst was simple: the company stayed profitable and lifted full year guidance, powered by NERLYNX net product revenue of US$53.6m and Q2 net income of US$8.2m.

The bigger story is less about one quarter and more about whether this profit trend can coexist with forecasts for weaker earnings in the years ahead. That tension between a stronger P&L today and a softer outlook is what will matter for holders of Puma Biotechnology.

Love that Puma Biotechnology is staying profitable today but concerned about forecasts for weaker earnings ahead? Take a look at the 19 high quality undiscovered gems for stocks that pair current profitability with stronger forward expectations.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$56.5m vs. US$52.4m (up about 8%)
• Net Income (Q2 2026 vs Q2 2025): US$8.2m vs. US$5.9m (up about 40%)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.16 per share vs. US$0.12 per share (up about 36%)
• NERLYNX Net Product Revenue (Q2 2026 vs Q2 2025): US$53.6m vs. US$49.2m (up about 9%)

Prefer a clear visual story instead of another wall of earnings tables and footnotes? See Puma Biotechnology's full financial picture, with a focus on valuation, in an easy-to-scan visual format in our company report for Puma Biotechnology.

Puma Biotechnology bull case anchored in NERLYNX delivery

Optimists argue Puma Biotechnology can keep NERLYNX growing while staying profitable and using that cash to fund a second act in alisertib. Q2 gives that view some real support. NERLYNX net product revenue reached US$53.6m with 2,929 ex factory bottles and double digit year on year bottle growth. That aligns with the narrative of stronger demand and better commercial execution. Full year NERLYNX guidance is raised to US$205m to US$209m and net income to US$17m to US$20m, which backs up talk of disciplined expense control rather than just revenue uplift. Cash of US$93.9m and a debt free balance sheet also fit the idea that management can fund Phase II alisertib work and prepare for possible Phase III without rushing to raise capital.

Bear case tests on concentration, starts and royalties

Bears focus on heavy reliance on a single drug, softening new starts and rising R&D spend. Q2 does not remove those concerns. NERLYNX still accounts for almost all product revenue, so concentration risk remains intact despite higher sales. New patient starts fell about 6% quarter on quarter even as total prescriptions and bottle volumes rose. That supports the fear that growth is leaning more on persistence and channel mix than on accelerating fresh demand. Management also trimmed royalty guidance to US$19m to US$22m, which is consistent with slower international shipments including China. R&D of US$18.9m and plans to fund multiple Phase II and possible Phase III alisertib trials show costs are moving higher. Profitability is intact today, yet the ingredients that worry the bear case are still present in the numbers.

After profit margins moved from 20.4% to 11.5% and earnings are forecast to decline 45.1% each year, review our risk analysis for Puma Biotechnology which shows 2 important warning signs

Stay Ahead With Simply Wall St

If Puma Biotechnology's profitability today alongside forecasts for weaker earnings has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a more attractive entry point. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the most important updates to your holdings. For longer term decisions, join the Community to compare your thinking with other investors and see how sentiment shifts over time. This combination can help you spot hidden catalysts or emerging risks early and keep you a step ahead of the market.

Seeking Alternatives Beyond Puma Biotechnology?

Fresh stock ideas can move quickly from quiet buildup to breakout momentum, while the window for clean entry points keeps dropping out of sight. Scan these under the radar for now and consider your options.

• Spot companies quietly building momentum before headlines catch up by reviewing the hand picked 78 resilient stocks with low risk scores that may help you avoid sharp drawdowns while it matters.
• Explore high conviction income ideas with staying power by working through the curated 8 dividend fortresses and see which cash generators still offer yields that have not been fully priced in yet.
• Review fast moving infrastructure themes supporting AI growth by checking the focused 55 AI infrastructure stocks and see which enablers could be setting up for the next phase of market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.